---
title: "Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295528768.md"
description: "Upstream Bio reported Q2 2026 revenue of $0.8M and a net loss of $39.7M, with diluted EPS at $(0.73). The company advanced its lead asset Verekitug through Phase 2 trials for severe asthma and CRSwNP, with Phase 3 trials planned for Q1 2027. R&D spending increased to support accelerated development. Maruho holds exclusive commercialization rights in Japan."
datetime: "2026-08-11T11:21:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295528768.md)
  - [en](https://longbridge.com/en/news/295528768.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295528768.md)
generator: "portal-rs"
---

# Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary

Upstream Bio, Inc. reported second-quarter 2026 results with revenue of $0.8M and a net loss attributable to common stockholders of $39.7M, or diluted EPS of $(0.73), largely unchanged from the year-ago quarter.

**Financial Highlights**

-   Revenue was $0.8M for 2Q 2026, down from $0.9M in 2Q 2025 (−17.5% YoY).
-   Net income: Net loss attributable to common stockholders was $39.7M for 2Q 2026, essentially flat versus a $40.0M loss in 2Q 2025.
-   Diluted EPS was $(0.73) for 2Q 2026 versus $(0.74) in 2Q 2025.

**Business Highlights**

-   Clinical progress: Verekitug advanced through Phase 2 with positive top-line results in chronic rhinosinusitis with nasal polyps (CRSwNP) reported September 2025 and in severe asthma reported February 2026; Phase 2 COPD enrollment is complete.
-   Development timeline: The company plans to initiate Phase 3 trials for severe asthma and CRSwNP in Q1 2027; Phase 2 long-term extension and COPD data are expected in H2 2027.
-   R&D and operations: Upstream increased R&D headcount and program spending, tracking indication-level costs for asthma, COPD and CRSwNP to support accelerated trials.
-   Collaborations and commercial strategy: Maruho holds exclusive Japan commercialization rights and will reimburse development costs, while Upstream Bio retains global R&D rights.

Original SEC Filing: Upstream Bio, Inc. \[ UPB \] - 10-Q - Aug. 11, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [UPB.US](https://longbridge.com/en/quote/UPB.US.md)

## Related News & Research

- [Upstream Bio plans Q1 2027 start for Phase 3 verekitug trials in severe asthma, nasal polyps](https://longbridge.com/en/news/297641472.md)
- [UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP](https://longbridge.com/en/news/295535838.md)
- [Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP](https://longbridge.com/en/news/295528626.md)
- [Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9](https://longbridge.com/en/news/298034950.md)
- [AbbVie Completes Acquisition of Apogee Therapeutics | ABBV Stock News](https://longbridge.com/en/news/297915640.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**